Cloprostenol
Research News and Information

Sunday, November 22, 2009

Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.

30 Jul 2009 PURPOSE: To assess the usefulness and tolerability of systematically switching glaucoma patients from latanoprost 0.005% and timolol 0.5% (Lat + Tim) to a fixed combination of travoprost 0.004%/timolol 0.5% (TTFC), and to record the effects of this ... Read more...

Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

26 Jul 2009 BACKGROUND: Benzalkonium chloride (BAC) is a common preservative used in ophthalmic solutions. The aim of this study was to compare the cytotoxic effects of BAC-containing ophthalmic solutions with a BAC-free ophthalmic solution using an organotypic ... Read more...

Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.

7 Jul 2009 OBJECTIVE: To compare the efficacy of brimonidine, dorzolamide, and brinzolamide in reducing intraocular pressure (IOP) when used as adjunctive therapy to a prostaglandin analog (PGA). DESIGN: Randomized, controlled, investigator-masked, ... Read more...

Latest indexed articles for 'Cloprostenol'

These are the very latest articles for this heading:

• Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. 30 Aug 2009
• Comment on Efficacy and tolerability of prostaglandin analogs. 30 Jul 2009
• Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. 30 Jul 2009
• Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. 26 Jul 2009
• Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. 7 Jul 2009
• Relative efficacy of prostaglandins. 29 Jun 2009
• Corneal thickness and glaucoma medications. 29 Jun 2009
• Beneficial effects on the reproductive performance of sows of administering prostaglandin analogues after farrowing. 25 Jun 2009
• Latisse: empirical discovery yields treatment for sparse eyelashes. 30 May 2009
• Bimatoprost 0.03% solution (latisse) for eyelash enhancement. 30 May 2009
• Meta-analysis of medical intervention for normal tension glaucoma. 15 May 2009
• Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost. 29 Apr 2009
• Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. 17 Apr 2009
• [Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials] 30 Mar 2009
• Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. 30 Mar 2009
• First-year treatment patterns among new initiators of topical prostaglandin analogs. 30 Mar 2009
• Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. 30 Mar 2009
• Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic. 30 Mar 2009
• The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. 30 Mar 2009
• Safety and effectiveness of topical bimatoprost. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Cloprostenol'

Definition: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.

Chemical name: 5-Heptenoic acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, (1alpha(Z),2beta(1E,3R*),3alpha,5alpha)-(+-)-

Registry Number: 40665-92-7

Descriptor UI: D003008

Alternative terms: Cloprostenol; Oestrophan; ICI-80,966; ICI 80,966; ICI80,966; Cloprostenol Sodium; Sodium, Cloprostenol; Cloprostenol Monosodium Salt; Monosodium Salt, Cloprostenol; Salt, Cloprostenol Monosodium; Estrumate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Luteolytic Agents;

Tree Number: D10.251.355.255.550.700.500.175; D23.469.700.670.175;

History Note: 91(79); was see under PROSTAGLANDINS F, SYNTHETIC 1979-90